Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.39 |
| ▸ | DPP4 | P27487 | 4/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.31 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22096884 | 0.92 | BCHE (0.41) | BCHEDPP4GNAI3GNAO1GNAI1 | |
| SCHEMBL19779675 | 0.81 | GAA (0.33) | BCHEDPP4DPP8DPP9DPP7 | |
| SCHEMBL20621211 | 0.80 | ACKR3 (0.39) | — | |
| SCHEMBL19880561 | 0.80 | ACKR3 (0.39) | — | |
| SCHEMBL19769009 | 0.80 | ACKR3 (0.39) | — | |
| SCHEMBL23491300 | 0.80 | BCHE (0.41) | BCHEDPP4GNAI3GNAO1GNAI1 | |
| SCHEMBL19779848 | 0.79 | TSHR (0.33) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL19779680 | 0.76 | BCHE (0.42) | BCHEDPP4GNAI3GNAO1GNAI1 | |
| SCHEMBL22096796 | 0.74 | TSHR (0.37) | BCHEGNAI3GNAO1GNAI1 | |
| SCHEMBL23491217 | 0.74 | SMN1; SMN2 (0.42) | BCHEDPP4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597377-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597377-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | BCHE 2060/4885DPP4 95/4885FAP 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.